Abaloparatide
As of the edition of 20 October 2026, Abaloparatide is a protein: marketed, first approved in 2017 (US); acts on PTH1R; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Protein
- Brand name
- Tymlos
- First approved
- 28 April 2017 (US)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- Theramex; 3 holders in all
- Registered trials
- 15, 3 stopped early
- Disease areas
- Bones, joints and muscles; Nutrition and metabolism; Injuries; Blood and lymph; Cancer
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Abaloparatide.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | Q03431 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 1 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 6 | 2 | 2 | 2 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 15 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Radius Health | Originator and Lead sponsor of trials | 2007 to now |
| Teijin Pharma | Applicant | 2021 to now |
| Theramex | Applicant | 2022 to now |